Log In
person
Y-mAbs Therapeutics Inc
YMAB
summarize
2 total product lines
calendar_month
Revenue as of 12/31/2023
| Reporting Segmentarrow_drop_up | Product Line | Amount (USD) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (USD) | Percentage |
| Cancer Treatment Products |
Branded Pharmaceuticals (outsourced)
These companies research, develop, and outsource the manufacturing of patented drugs.
|
84.32M | 99.41% |
| Cancer Treatment Products |
Pharmaceutical Patent Licensing
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
0.5M | 0.59% |
| keyboard_arrow_down |
Cancer Treatment Products
Branded Pharmaceuticals (outsourced)
|
84.32M | 99.41% |
| keyboard_arrow_right |
These companies research, develop, and outsource the manufacturing of patented drugs.
|
||
| keyboard_arrow_down |
Cancer Treatment Products
Pharmaceutical Patent Licensing
|
0.5M | 0.59% |
| keyboard_arrow_right |
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
||